AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for P2Y purinoceptor 12

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9H244

UPID:

P2Y12_HUMAN

Alternative names:

ADP-glucose receptor; P2T(AC); P2Y(AC); P2Y(cyc); P2Y12 platelet ADP receptor; SP1999

Alternative UPACC:

Q9H244; D3DNJ5; Q546J7

Background:

P2Y purinoceptor 12, also known as P2Y12 platelet ADP receptor, plays a crucial role in the regulation of platelet aggregation and blood coagulation. This receptor, activated by ADP and ATP, inhibits the adenylyl cyclase second messenger system, essential for normal platelet function.

Therapeutic significance:

Mutations in P2Y purinoceptor 12 are linked to Bleeding disorder, platelet-type, 8, characterized by impaired platelet response and excessive bleeding. Targeting P2Y12 receptor offers a promising approach for managing this condition and enhancing hemostasis.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.